Clinical trial · Interventional
Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Merge the data of ultrasound with that of the anatomical and functional MRI is necessary since the high dose rate Curietherapy is carried out under ultrasound guidance. The investigators will recruit prostate cancer patients to evaluate the quality of the data, their sensitivity to exam conditions (patient position, volume of endorectal probe, gold grains implanted before intensity modulated radiotherapy , IMRT) and to merge data from different sources with the purpose of estimating the opportunities of integration treatment plan for Curietherapy broadband. The nuclear magnetic resonance imaging provides precise anatomical study, but also provides access to a functional approach to the tumor mapping of water diffusion coefficient (DW-MRI), for dynamic imaging with injection contrast agent (DCE-MRI) and finally by spectroscopic imaging (IRMS). This multimodality imaging project is part of a multidisciplinary context, involving close collaboration between clinicians, medical physicists, and physicists of the teams participating in this project (Institut Gustave Roussy and U2R2M-CIERM hospital Kremlin-Bicetre).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Functional magnetic resonance imaging | Device | — | UNRESOLVED |
| Ultrasound | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients with prostate cancer
- interventionNames
- Device: Functional magnetic resonance imaging
- Device: Ultrasound
Primary outcomes (1)
- measure
- Quality of imaging [good/good enough/not good enough]
- timeFrame
- Assessed six weeks after inclusion
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Patients with prostate cancer biopsy-proven, intermediate or high risk (according to D'Amico Classification), for which radiotherapy is indicated. * Accepting the imaging tests. * Age \<70 years. * Informed consent signed. Exclusion Criteria: * Mental pathology that can interfere with the proper conduct of the study; * Claustrophobia; * Severe heart or respiratory disorder that can make it difficult to achieve relatively long imaging tests * Contraindications to magnetic resonance imaging (MRI) 1. pacemaker, other electronic appliance (depending on model); 2. heart valve, intra-cranial clip aneurysm, cerebral ventricular bypass valve (depending on model); 3. intraocular metallic foreign bodies (chips), and other locations, according to the site to discuss. 4. metal tracheostomy cannula; 5. endovascular stent or vascular embolization coils placed within six weeks in advance; 6. the impediments to a long examination with spectroscopy sequence of ten to twenty minutes: major tremors, inability to lie more than 30 minutes; 7. local sources of magnetic distortion which is sensitive spectroscopic imaging: hip replacement, prostate biopsy older than six weeks.
References
Publications (0)
Data not yet available